Hui Hui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hui Hui has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Qinglong Guo
School of Basic Medicine and Clinical Pharmacy China Pharmaceutical University Nanjing Jiangsu China
15 shared publications Hui Li
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of -Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China
14 shared publicationsMengyuan Zhu
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of -Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China
8 shared publicationsPo Hu
School of pharmacy Nanjing University of Chinese Medicine Nanjing China
8 shared publicationsHongzheng Wang
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China
7 shared publicationsJingyan Xu
Department of Hematology The Affiliated DrumTower Hospital of Nanjing University Medical School Nanjing China
7 shared publications
Latest Publications
- Open Access
- 5 December 2025
- Published by Elsevier in Pharmacological Research
- Vol. 222, 108050
Overcoming ELDR-mediated cancer cell survival in vitro and in vivo via sphingomyelin-driven TRPML1 inactivation and TFEB suppression through lysosomal HSP70 targeting
- 5 December 2025
- Published by Elsevier in Pharmacological Research
- Vol. 222, 108050
Open AccessOvercoming ELDR-mediated cancer cell survival in vitro and in vivo via sphingomyelin-driven TRPML1 inactivation and TFEB suppression through lysosomal HSP70 targeting
- Open Access
- 22 October 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (20) , e71167
Chidamide Accelerates the Death of Senescence‐Like Diffuse Large B‐Cell Lymphoma Cells With TP53 Mutation Induced by Doxorubicin
Diffuse large B‐cell lymphoma (DLBCL), a heterogeneous malignancy characterized by distinct genetic and clinical subtypes, remains a therapeutic challenge despite standard R‐CHOP chemotherapy. This study systematically investigated the synergistic anti‐tumor efficacy and mechanism of the histone deacetylase inhibitor chidamide (CHI) combined with doxorubicin (DOX) in DLBCL models. Through multimodal experimental approaches including CCK8 proliferation assays, senescence‐associated β‐galactosidase (SA‐β‐gal) staining analysis, comet assay for DNA damage quantification, and comprehensive western blotting for molecular mechanism elucidation, we identified a potent synergistic interaction between CHI and DOX. By constructing a xenograft tumor model, the synergistic effect of the two drugs and its mechanism in vivo were confirmed. Our research found that CHI showed cell cycle inhibition and apoptosis induction effects on DLBCL cells. When combined with DOX, both synergistically inhibited the proliferation of DLBCL cells and promoted death of DOX‐induced senescent cells. Preliminary mechanism studies revealed that CHI can reduce the level of mutant p53, inhibit cell senescence, and induce irreparable DNA damage in DOX‐induced senescent tumor cells, ultimately leading them into programmed apoptosis. Thus, the “One‐two punch” strategy increased the sensitivity of p53‐mutated DLBCL cells to CHI. In summary, our study demonstrates that CHI synergizes with DOX to suppress DLBCL and presents a promising strategy to augment the therapeutic efficacy of DOX.
- 22 October 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (20) , e71167
Open AccessChidamide Accelerates the Death of Senescence‐Like Diffuse Large B‐Cell Lymphoma Cells With TP53 Mutation Induced by Doxorubicin
Diffuse large B‐cell lymphoma (DLBCL), a heterogeneous malignancy characterized by distinct genetic and clinical subtypes, remains a therapeutic challenge despite standard R‐CHOP chemotherapy. This study systematically investigated the synergistic anti‐tumor efficacy and mechanism of the histone deacetylase inhibitor chidamide (CHI) combined with doxorubicin (DOX) in DLBCL models. Through multimodal experimental approaches including CCK8 proliferation assays, senescence‐associated β‐galactosidase (SA‐β‐gal) staining analysis, comet assay for DNA damage quantification, and comprehensive western blotting for molecular mechanism elucidation, we identified a potent synergistic interaction between CHI and DOX. By constructing a xenograft tumor model, the synergistic effect of the two drugs and its mechanism in vivo were confirmed. Our research found that CHI showed cell cycle inhibition and apoptosis induction effects on DLBCL cells. When combined with DOX, both synergistically inhibited the proliferation of DLBCL cells and promoted death of DOX‐induced senescent cells. Preliminary mechanism studies revealed that CHI can reduce the level of mutant p53, inhibit cell senescence, and induce irreparable DNA damage in DOX‐induced senescent tumor cells, ultimately leading them into programmed apoptosis. Thus, the “One‐two punch” strategy increased the sensitivity of p53‐mutated DLBCL cells to CHI. In summary, our study demonstrates that CHI synergizes with DOX to suppress DLBCL and presents a promising strategy to augment the therapeutic efficacy of DOX.
- Open Access
- 25 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e15313
Activation of Lysosomal Retrograde Transport Triggers TPC1‐IP3R1 Ca 2+ Crosstalk at Lysosome‐ER MCSs Leading to Lethal Depleting of ER Calcium
Inter‐organellar signaling linkages in oncology are increasingly elucidated. However, the impact of lysosome‐endoplasmic reticulum (ER) interaction on tumor cell fate remains relatively unexplored. A novel interaction between lysosomes and the ER, mediated by the flavonoid LW‐213 through targeting LIMP2 (lysosomal integral membrane protein type 2)to activate a lysosomal repair pathway, is identified in acute myeloid leukemia (AML). This leads to activated RAB7A activity, enhancing lysosomal retrograde transport to the perinuclear region and increasing contact at lysosome‐ER membrane contact sites (MCSs). Close proximity of TPC1 to IP3R1 at these sites generates a concentrated calcium microdomain, triggering Ca 2+ ‐induced Ca 2+ release, which causes cytoplasmic calcium turbulence and two distinct calcium tides. This excessive calcium efflux depletes ER calcium stores, triggering lethal ER stress‐induced apoptosis. Interestingly, altering TPC1 expression levels in HeLa cells affected these calcium dynamics, replicating AML‐specific mechanisms when overexpressed. Subsequent studies using BALB/c xenograft models with wild‐type and LIMP2‐knockout THP1 cells, along with ICR mice toxicity models, confirmed LW‐213′s significant tumor growth inhibition with minimal toxicity. These findings underscore the potential of targeting lysosomal‐ER calcium crosstalk as an innovative approach to cancer treatment, highlighting the therapeutic promise of LW‐213 in managing tumor cell fate through modulating organellar interactions.
- 25 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e15313
Open AccessActivation of Lysosomal Retrograde Transport Triggers TPC1‐IP3R1 Ca 2+ Crosstalk at Lysosome‐ER MCSs Leading to Lethal Depleting of ER Calcium
Inter‐organellar signaling linkages in oncology are increasingly elucidated. However, the impact of lysosome‐endoplasmic reticulum (ER) interaction on tumor cell fate remains relatively unexplored. A novel interaction between lysosomes and the ER, mediated by the flavonoid LW‐213 through targeting LIMP2 (lysosomal integral membrane protein type 2)to activate a lysosomal repair pathway, is identified in acute myeloid leukemia (AML). This leads to activated RAB7A activity, enhancing lysosomal retrograde transport to the perinuclear region and increasing contact at lysosome‐ER membrane contact sites (MCSs). Close proximity of TPC1 to IP3R1 at these sites generates a concentrated calcium microdomain, triggering Ca 2+ ‐induced Ca 2+ release, which causes cytoplasmic calcium turbulence and two distinct calcium tides. This excessive calcium efflux depletes ER calcium stores, triggering lethal ER stress‐induced apoptosis. Interestingly, altering TPC1 expression levels in HeLa cells affected these calcium dynamics, replicating AML‐specific mechanisms when overexpressed. Subsequent studies using BALB/c xenograft models with wild‐type and LIMP2‐knockout THP1 cells, along with ICR mice toxicity models, confirmed LW‐213′s significant tumor growth inhibition with minimal toxicity. These findings underscore the potential of targeting lysosomal‐ER calcium crosstalk as an innovative approach to cancer treatment, highlighting the therapeutic promise of LW‐213 in managing tumor cell fate through modulating organellar interactions.
- 10 May 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (9) , e70622
Therapeutic Effect of V8 Affecting Mitophagy and Endoplasmic Reticulum Stress in Acute Myeloid Leukemia Mediated by ROS and CHOP Signaling
Acute myeloid leukemia (AML) is characterized by the malignant proliferation of abnormally or poorly differentiated myeloid cells in the hematopoietic system. However, there is a lack of effective drugs for treating non‐M3 AML. V8, a newly synthesized derivative of the natural flavonoid wogonin, which is a potential anticancer drug, has demonstrated significant antitumor activity both in vitro and in vivo. Here, we investigated the effects of V8 on AML cell lines and primary AML cells as well as its underlying mechanisms. Our results showed that V8 exerted significant concentration‐dependent growth inhibition and apoptosis induction in AML cells, accompanied by characteristic pathological features including lysosomal functions suppression, mitochondrial dysfunction, and endoplasmic reticulum stress (ERS) activation. Mechanistic investigations revealed that V8 induced mitochondrial membrane potential collapse through elevation of intracellular reactive oxygen species (ROS) levels, while concurrently blocking mitophagy via lysosomal functional inhibition. Furthermore, V8 selectively activated the PERK/p‐eIF2α/ATF4 and IRE1α/XBP1 signaling axes of ERS, ultimately triggering CHOP‐mediated apoptosis through the ERS‐specific pathway. In vivo studies confirmed that V8 treatment significantly prolonged survival duration in NOD/SCID mice bearing primary AML xenografts and suppressed tumor progression in BALB/c nude mice with U937 cell xenografts, with antitumor efficacy closely associated with CHOP‐dependent ERS pathway modulation. These findings not only elucidate the multi‐targeted mechanism of V8 against AML through coordinated regulation of the ROS‐mitochondria‐lysosome‐ERS signaling network, but also provide critical theoretical foundations for developing natural product‐based therapeutics for AML. The multi‐pathway synergistic characteristics exhibited by V8 underscore its considerable potential as a clinically translatable candidate drug.
- 10 May 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (9) , e70622
Therapeutic Effect of V8 Affecting Mitophagy and Endoplasmic Reticulum Stress in Acute Myeloid Leukemia Mediated by ROS and CHOP Signaling
Acute myeloid leukemia (AML) is characterized by the malignant proliferation of abnormally or poorly differentiated myeloid cells in the hematopoietic system. However, there is a lack of effective drugs for treating non‐M3 AML. V8, a newly synthesized derivative of the natural flavonoid wogonin, which is a potential anticancer drug, has demonstrated significant antitumor activity both in vitro and in vivo. Here, we investigated the effects of V8 on AML cell lines and primary AML cells as well as its underlying mechanisms. Our results showed that V8 exerted significant concentration‐dependent growth inhibition and apoptosis induction in AML cells, accompanied by characteristic pathological features including lysosomal functions suppression, mitochondrial dysfunction, and endoplasmic reticulum stress (ERS) activation. Mechanistic investigations revealed that V8 induced mitochondrial membrane potential collapse through elevation of intracellular reactive oxygen species (ROS) levels, while concurrently blocking mitophagy via lysosomal functional inhibition. Furthermore, V8 selectively activated the PERK/p‐eIF2α/ATF4 and IRE1α/XBP1 signaling axes of ERS, ultimately triggering CHOP‐mediated apoptosis through the ERS‐specific pathway. In vivo studies confirmed that V8 treatment significantly prolonged survival duration in NOD/SCID mice bearing primary AML xenografts and suppressed tumor progression in BALB/c nude mice with U937 cell xenografts, with antitumor efficacy closely associated with CHOP‐dependent ERS pathway modulation. These findings not only elucidate the multi‐targeted mechanism of V8 against AML through coordinated regulation of the ROS‐mitochondria‐lysosome‐ERS signaling network, but also provide critical theoretical foundations for developing natural product‐based therapeutics for AML. The multi‐pathway synergistic characteristics exhibited by V8 underscore its considerable potential as a clinically translatable candidate drug.
- 23 August 2024
- Published by Elsevier in Phytomedicine
- Vol. 134, 155958
LW-213, a derivative of wogonin, triggers reticulophagy-mediated cell death in NSCLC via lysosomal damage combined with NPC1 inhibition
- 23 August 2024
- Published by Elsevier in Phytomedicine
- Vol. 134, 155958
LW-213, a derivative of wogonin, triggers reticulophagy-mediated cell death in NSCLC via lysosomal damage combined with NPC1 inhibition
- 20 May 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 76 (8) , 1006-1017
GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition
GL-V9 exhibited anti-tumour effects on various types of tumours. This study aimed to verify if GL-V9 synergized with oxaliplatin in suppressing colorectal cancer (CRC) and to explore the synergistic mechanism. The synergy effect was tested by MTT assays and the mechanism was examined by comet assay, western blotting and immunohistochemistry (IHC). Xenograft model was constructed to substantiated the synergy effect and its mechanism in vivo. GL-V9 was verified to enhance the DNA damage effect of oxaliplatin, so as to synergistically suppress colon cancer cells in vitro and in vivo. In HCT-116 cells, GL-V9 accelerated the degradation of Wee1 and induced the abrogation of cell cycle arrest and mis-entry into mitosis, bypassing the DNA damage response caused by oxaliplatin. Our findings suggested that GL-V9 binding to HSP90 was responsible for the degradation of Wee1 and the vulnerability of colon cancer cells to oxaliplatin. Functionally, overexpression of either HSP90 or WEE1 annulled the synergistic effect of GL-V9 and oxaliplatin. Collectively, our findings revealed that GL-V9 synergized with oxaliplatin to suppress CRC and displayed a promising strategy to improve the efficacy of oxaliplatin.
- 20 May 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 76 (8) , 1006-1017
GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition
GL-V9 exhibited anti-tumour effects on various types of tumours. This study aimed to verify if GL-V9 synergized with oxaliplatin in suppressing colorectal cancer (CRC) and to explore the synergistic mechanism. The synergy effect was tested by MTT assays and the mechanism was examined by comet assay, western blotting and immunohistochemistry (IHC). Xenograft model was constructed to substantiated the synergy effect and its mechanism in vivo. GL-V9 was verified to enhance the DNA damage effect of oxaliplatin, so as to synergistically suppress colon cancer cells in vitro and in vivo. In HCT-116 cells, GL-V9 accelerated the degradation of Wee1 and induced the abrogation of cell cycle arrest and mis-entry into mitosis, bypassing the DNA damage response caused by oxaliplatin. Our findings suggested that GL-V9 binding to HSP90 was responsible for the degradation of Wee1 and the vulnerability of colon cancer cells to oxaliplatin. Functionally, overexpression of either HSP90 or WEE1 annulled the synergistic effect of GL-V9 and oxaliplatin. Collectively, our findings revealed that GL-V9 synergized with oxaliplatin to suppress CRC and displayed a promising strategy to improve the efficacy of oxaliplatin.
- 6 October 2023
- Published by Elsevier in Cancer Letters
- Vol. 577, 216435
LW-213 induces immunogenic tumor cell death via ER stress mediated by lysosomal TRPML1
- 6 October 2023
- Published by Elsevier in Cancer Letters
- Vol. 577, 216435
LW-213 induces immunogenic tumor cell death via ER stress mediated by lysosomal TRPML1
- Open Access
- 23 March 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (3) , e1229
Targeting lysosomal HSP70 induces acid sphingomyelinase‐mediated disturbance of lipid metabolism and leads to cell death in T cell malignancies
Background: T cell malignancies proliferate vigorously, are highly dependent on lysosomal function, with limited therapeutic options. Deregulation of lysosomal structure and function has been confirmed to be a key role in the treatment of hematologic malignant disease.Methods: Cell counting kit 8 and Annexin V/PI staining were used to assess the cell viability and apoptosis rate. Flow cytometry, liquid chromatography mass spectrometry, immunofluorescence and western blot were performed to detect the effect on lysosomes. Drug affinity responsive target stability, molecular docking and cellular thermal shift assay were employed to confirm the target protein of V8 on lysosomes. A xenograft model was constructed inNOD/SCIDmice to assess the effect and mechanism.Results: V8, a new lysosomotropic compound, could be rapidly trapped by lysosomes and accumulation in lysosomes, contributing to lysosomal‐dependent cell death by evoking lysosomal membrane permeabilization (LMP), accompanied with disrupted lysosome and autophagic flux. Mechanistically, heat shock protein 70 (HSP70) was identified as the binding target of V8 in lysosome. As a downstream effect of targeting HSP70, enzymatic activity of acid sphingomyelinase (ASM) was inhibited, which induced disturbance of lipid metabolism, instability of lysosomal membrane, and leakage of cathepsin B and D, leading to LMP‐mediated cell death. In vivo study showed V8 well controlled the growth of the tumour and confirmed lysosomal cell death induced by V8.Conclusions: Collectively, this study suggests targeting lysosomal HSP70‐ASM axis by V8 illustrates the great value of drug therapy for T cell malignancies and the unlimited potential of lysosomal targeting for cancer therapy.
- 23 March 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (3) , e1229
Open AccessTargeting lysosomal HSP70 induces acid sphingomyelinase‐mediated disturbance of lipid metabolism and leads to cell death in T cell malignancies
Background: T cell malignancies proliferate vigorously, are highly dependent on lysosomal function, with limited therapeutic options. Deregulation of lysosomal structure and function has been confirmed to be a key role in the treatment of hematologic malignant disease.Methods: Cell counting kit 8 and Annexin V/PI staining were used to assess the cell viability and apoptosis rate. Flow cytometry, liquid chromatography mass spectrometry, immunofluorescence and western blot were performed to detect the effect on lysosomes. Drug affinity responsive target stability, molecular docking and cellular thermal shift assay were employed to confirm the target protein of V8 on lysosomes. A xenograft model was constructed inNOD/SCIDmice to assess the effect and mechanism.Results: V8, a new lysosomotropic compound, could be rapidly trapped by lysosomes and accumulation in lysosomes, contributing to lysosomal‐dependent cell death by evoking lysosomal membrane permeabilization (LMP), accompanied with disrupted lysosome and autophagic flux. Mechanistically, heat shock protein 70 (HSP70) was identified as the binding target of V8 in lysosome. As a downstream effect of targeting HSP70, enzymatic activity of acid sphingomyelinase (ASM) was inhibited, which induced disturbance of lipid metabolism, instability of lysosomal membrane, and leakage of cathepsin B and D, leading to LMP‐mediated cell death. In vivo study showed V8 well controlled the growth of the tumour and confirmed lysosomal cell death induced by V8.Conclusions: Collectively, this study suggests targeting lysosomal HSP70‐ASM axis by V8 illustrates the great value of drug therapy for T cell malignancies and the unlimited potential of lysosomal targeting for cancer therapy.
- Open Access
- 22 February 2023
- Published by Springer Nature in Research Square
Therapeutic effect of V8 affecting mitophagy and endoplasmic reticulum stress in acute myeloid leukemia mediated by ROS and CHOP signaling
Acute myeloid leukemia (AML) is a disease of malignant proliferation of abnormally or poorly differentiated myeloid cells of the hematopoietic system. The clinical treatments of non-M3 AML are experiencing a lack of effective drugs. V8 is a newly synthesized derivative of the natural flavonoid wogonin, which belongs to the potential anticancer drug, and has shown significant antitumor activityin vitroandin vivo. In this study, we investigated the effects of V8 on AML cell lines and primary AML cells and the underlying mechanisms. The results showed that V8 inhibited the growth and induced the apoptosis of AML cell lines (ME-1, Kasumi-1, and U937) and primary AML cells in a concentration-dependent manner. Meanwhile, we revealed that V8-induced apoptosis was accompanied by mitochondrial injury, such as the reduction of mitochondrial membrane potential and ATP production, activation of endoplasmic reticulum stress (ERS) characterized by GRP78 and caspase-12 expression upregulation. Mechanism studies have shown that V8 induced mitochondrial injury and inhibited mitophagy via elevating the intracellular ROS level. In addition, V8 activated PERK-p-eIF2α-ATF4 and Ire1α-XBP1 pathways and induced apoptosis of AML cells via selectively activating CHOP. Correspondingly, the degree of apoptosis and expression of apoptosis-related proteins were alleviated after the elimination of cytoplasmic ROS with N-Acetyl-L-cysteine (NAC) and knocking out CHOP in the cells by transfection with CHOP shRNA, implicating that mitochondrial injury-triggered upregulation of ROS and CHOP played an important role in V8-induced apoptosis of AML cells. In primary AML cells-bearingNOD/SCIDmice model and U937 cells-inoculatingBALB/cnude mice xenografts transplantation tumor model, administration of V8 markedly prolonged survival time and inhibited the xenografts growth via CHOP-mediated ERSin vivo. In conclusion, our study provides a new insight into the mechanism of V8-induced apoptosis, suggesting the potential of V8 as a promising agent against AML.
- 22 February 2023
- Published by Springer Nature in Research Square
Open AccessTherapeutic effect of V8 affecting mitophagy and endoplasmic reticulum stress in acute myeloid leukemia mediated by ROS and CHOP signaling
Acute myeloid leukemia (AML) is a disease of malignant proliferation of abnormally or poorly differentiated myeloid cells of the hematopoietic system. The clinical treatments of non-M3 AML are experiencing a lack of effective drugs. V8 is a newly synthesized derivative of the natural flavonoid wogonin, which belongs to the potential anticancer drug, and has shown significant antitumor activityin vitroandin vivo. In this study, we investigated the effects of V8 on AML cell lines and primary AML cells and the underlying mechanisms. The results showed that V8 inhibited the growth and induced the apoptosis of AML cell lines (ME-1, Kasumi-1, and U937) and primary AML cells in a concentration-dependent manner. Meanwhile, we revealed that V8-induced apoptosis was accompanied by mitochondrial injury, such as the reduction of mitochondrial membrane potential and ATP production, activation of endoplasmic reticulum stress (ERS) characterized by GRP78 and caspase-12 expression upregulation. Mechanism studies have shown that V8 induced mitochondrial injury and inhibited mitophagy via elevating the intracellular ROS level. In addition, V8 activated PERK-p-eIF2α-ATF4 and Ire1α-XBP1 pathways and induced apoptosis of AML cells via selectively activating CHOP. Correspondingly, the degree of apoptosis and expression of apoptosis-related proteins were alleviated after the elimination of cytoplasmic ROS with N-Acetyl-L-cysteine (NAC) and knocking out CHOP in the cells by transfection with CHOP shRNA, implicating that mitochondrial injury-triggered upregulation of ROS and CHOP played an important role in V8-induced apoptosis of AML cells. In primary AML cells-bearingNOD/SCIDmice model and U937 cells-inoculatingBALB/cnude mice xenografts transplantation tumor model, administration of V8 markedly prolonged survival time and inhibited the xenografts growth via CHOP-mediated ERSin vivo. In conclusion, our study provides a new insight into the mechanism of V8-induced apoptosis, suggesting the potential of V8 as a promising agent against AML.
- 17 February 2023
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 24 (2) , 101-114
Multiple characteristic alterations and available therapeutic strategies of cellular senescence
Given its state of stable proliferative inhibition, cellular senescence is primarily depicted as a critical mechanism by which organisms delay the progress
- 17 February 2023
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 24 (2) , 101-114
Multiple characteristic alterations and available therapeutic strategies of cellular senescence
Given its state of stable proliferative inhibition, cellular senescence is primarily depicted as a critical mechanism by which organisms delay the progress